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ORIGINAL CLINICAL SCIENCE STUDIES
There has been a natural reluctance to treat major
aortic graft infection (MAGI) with total graft excision
(TGE) and in situ revascularization, because of the risk
of reinfection. However, although this probably
applies to standard prostheses, there is increasing evi-
dence that in situ replacement with an antibiotic-
bonded graft confers the benefits of anatomical recon-
struction (higher flow, enhanced patency, maintenance
of internal iliac circulation), while avoiding the prob-
lems of TGE and extra-anatomical bypass grafting
(longer procedure, lower flow, poorer patency, gluteal
ischemia, aortic stump blowout) and without incur-
ring the inevitable risk of secondary infection.1-3
Moreover, for those patients in whom the infective
process involves the suprarenal vessels, extra-anatomi-
cal bypass grafting is not an option, and some form of
anatomical revascularization is unavoidable.
After Strachan’s initial report of using a rifampicin-
bonded prosthesis,4 we reported our preliminary expe-
rience of five patients who had MAGI and were suc-
cessfully treated with this technique.3 Our experience
has now increased to 11 patients, and this report high-
lights the evolving modifications to our operative tech-
nique, early and late outcomes, and the problems asso-
ciated with the emergence of methicillin-resistant
Staphylococcus aureus (MRSA) graft infections.
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Purpose: Prosthetic graft infection after aortic aneurysm surgery is a life-threatening com-
plication. Treatment options include total graft excision and extra-anatomic bypass graft-
ing or in situ replacement of the graft. The latter option is gaining increasing popularity,
but the long-term outcome remains uncertain, particularly in light of the increasing preva-
lence of methicillin-resistant Staphylococcus aureus (MRSA). We performed a prospective
nonrandomized study to assess the outcome after graft excision and in situ replacement
with a rifampicin-bonded prosthesis for the treatment of major aortic graft infection. 
Methods: In a 6-year period from January 1992 to December 1997, 11 patients (eight
men, three women) with major aortic graft infection underwent total graft excision and
in situ replacement with a rifampicin-bonded prosthesis. The median age of the patients
was 66 years (range, 49 to 78 years). Four patients had a hemorrhage from an aortoen-
teric fistula, three had a retroperitoneal abscess, two had graft occlusion, one had a peri-
graft collection shown by means of computed tomography, and one had a ruptured
suprarenal false aneurysm. Organisms were cultured from 10 patients. 
Results: MRSA was isolated in two patients, both of whom had originally undergone
repair of a ruptured abdominal aortic aneurysm. Two patients died (18.2%) within 30
days, and three patients (27.6%) had nonfatal complications (peritoneal candidiasis,
transient renal impairment, and profound anorexia). Two patients died late in the fol-
low-up period. Seven patients remain alive and clinically free of infection.
Conclusion: The long-term results after total graft excision and in situ replacement with
a rifampicin-bonded prosthesis appear to be favorable. However, MRSA aortic graft
infection appears to be associated with a poor prognosis. (J Vasc Surg 1999;30:92-8.)
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MATERIALS AND METHODS
Preoperative assessment. Between Jan 1,
1992, and Dec 31, 1997, 11 patients with MAGI
underwent TGE and in situ revascularization with a
rifampicin-bonded prosthesis. During the same peri-
od, one other patient with MAGI underwent TGE
and an extra-anatomical bypass grafting procedure
(surgeon preference), but this patient died in the
early postoperative period. All patients were treated
with intravenous cefuroxime and metronidazole
when the diagnosis of MAGI was suspected, but this
treatment was revised if subsequent cultures revealed
resistant organisms. Those patients who had acute
emergencies (eg, massive gastrointestinal hemor-
rhage) did not undergo any preoperative investiga-
tions. The remainder underwent preoperative com-
puted tomography (CT) scanning, but angiography
was only used at the discretion of the operating sur-
geon. With regard to the duration of infection,
seven of the 11 patients had acute emergencies with
no earlier illness. The range of earlier illness in the
remaining four patients was 5 to 17 days.
Operative technique. The first priority was
control of the diaphragmatic aorta to prevent
uncontrollable hemorrhage during the procedure.
After this, the juxtarenal aorta was exposed either by
means of reflection of the right colon, duodenum,
and pancreatic head medially or by means of medial
visceral rotation of the spleen, stomach, left colon,
pancreas, and left kidney. No attempt was made to
directly expose the aorta or graft through the
retroperitoneal inflammatory mass. By using the
above approaches, it is usually possible to mobilize a
segment of the aorta immediately below the renal
arteries that is not involved in the inflammatory
process. However, for those with juxtarenal involve-
ment, the suprarenal aorta and renal arteries were
mobilized, allowing insertion of balloon irrigation
catheters in the renal artery orifices to allow cold
perfusion of the kidneys while the suprarenal aorta
was clamped.5 An important modification to our
original technique has been used in patients with
massive gastrointestinal hemorrhage and involves
inflation of an aortic balloon catheter (inserted via
the femoral artery) at the level of the proximal false
aneurysm. Once this has been achieved, dissection
can proceed in a more controlled manner while the
anesthetist stabilizes the patient.
Once proximal control was achieved, the distal
anastomoses were mobilized, and the patient was
systemically treated with heparin (5000 IU). The
aorta was then cross-clamped, and the aorta/graft
was opened posterolaterally or posteromedially (ie,
well away from the inflammatory mass). Any defect
in the bowel was then repaired or resected, as appro-
priate. A presized gelatin-impregnated Dacron pros-
thesis (Gelsoft, Vascutek, UK) was then irrigated
with 600 mg rifampicin, which had been reconsti-
tuted in 10 to 15 mL sterile water.
The graft was left to soak in the rifampicin solu-
tion for 20 minutes in the manner described by
Strachan4; during this time, the original graft was
excised entirely, specimens of graft, anastomosis, and
perigraft tissue was sent for microbiological culture,
and the retroperitoneum was debrided. It can often
be difficult to identify the ureters in the inflammatory
mass, therefore the tunnel tracks were debrided as
much as was safely possible and then irrigated with
aqueous iodine. The new prosthesis was then tun-
neled and anastomosed in the usual manner. After this
was completed, the graft was covered with retroperi-
toneum, omentum, or both where possible; specific
care was taken to exclude the bowel from the graft. In
four patients, Foley catheters were also placed within
the retroperitoneum to permit postoperative antibiot-
ic irrigation, in the manner described by Quick.6
These remained in situ for 10 days or until there was
resistance to injection.
Postoperative care. Systemic antibiotics were
continued for 2 weeks postoperatively. Only in the
two patients in whom MRSA was isolated did the
original systemic antibiotic therapy have to be
changed. Thereafter, the patient was changed to an
appropriate oral antibiotic regimen for 6 more weeks.
The decision to stop antibiotic therapy at 6 weeks
was based on microbiological advice, provided there
was no evidence of ongoing infection, either on
blood cultures or on a clinical basis. Patients found to
have MRSA graft infections had a tunneled Hickman
line inserted into a central vein and were prescribed
systemic vancomycin or teicoplanin for 6 weeks, or
until there was no evidence of ongoing systemic
infection. Three to 6 months postoperatively, all sur-
vivors underwent a 111Indium-labeled white cell scan
to exclude residual infection.7,8 Patients subsequent-
ly were examined in the outpatient clinic, but two
were lost to follow-up, one at 12 months and one at
15 months, despite repeated letters to the patients
and their family doctors.
RESULTS
Eleven patients (eight men, three women) with a
median age of 66 years (range, 49 to 78 years)
underwent TGE plus in situ replacement with a
rifampicin-bonded prosthesis for the treatment of
MAGI. The original vascular procedure was elective
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aneurysm repair in four patients and repair of a rup-
tured aneurysm in three, whereas four patients had
undergone elective aortobifemoral bypass grafting
procedures for occlusive disease. Five patients were
treated within 6 months of their original surgery
(including all those undergoing operation for rup-
tured aneurysm), two were treated within 6 to 12
months of their original surgery, and four were treat-
ed after 4 years or longer had elapsed.
Table I summarizes the clinical presentation and
30-day morbidity and mortality rates in the 11
patients, some of whom had multiple clinical fea-
tures. Four of the 11 patients had acute emergen-
cies, with massive hemorrhage from an aortaenteric
fistula, and three patients had large retroperitoneal
abscesses. Two patients had graft occlusion, one of
which was in coassociation with a false aneurysm of
the proximal anastomosis. One patient had a peri-
graft collection, which on CT scan demonstrated an
air-fluid interface. The remaining patient, who had
undergone elective repair of an aneurysm 5 months
earlier, had a ruptured suprarenal false aneurysm.
Bacteriological cultures yielded a number of dif-
ferent organisms from the 11 patients. Only one
patient had a culture that was negative for bacteria
(she had been on systemic antibiotics for 2 weeks
preoperatively), whereas the remaining patients had
one or more organisms cultured. However, unlike
our initial experience,3 two of the patients treated
later in our extended series had MRSA cultured
from the excised grafts. Both of these patients had
originally undergone emergency repair of a ruptured
aortic aneurysm, both were treated for emergencies
(one for acute myocardial infarction, aortoenteric
fistula, and retroperitoneal abscess and one for col-
lapse and infected retroperitoneal hematoma), and
we were unaware of the bacteriological diagnosis for
either patient before dealing with their infected
grafts. One of the MRSA patients had retroperi-
toneal catheters inserted into an infected retroperi-
toneal hematoma at the time of TGE and in situ
revascularization.
Two patients (18.2%) died within 30 days, and
three patients (27.6%) sustained nonfatal complica-
tions. A 73-year-old man, who had undergone repair
of a ruptured aneurysm 3 months earlier, had an
aortoenteric fistula and a retroperitoneal abscess and
died after sustaining biliary peritonitis. He initially
went to another center with collapse and an acute
myocardial infarction. The second death occurred in
a 46-year-old woman who had an MRSA infection
of a retroperitoneal hematoma after repair of a rup-
tured aneurysm 6 weeks earlier. This patient received
systemic and retroperitoneal vancomycin for 26
days; but just before discharge, she sustained a car-
diac arrest after a massive intraperitoneal hemor-
rhage. Despite aggressive resuscitation and a further
TGE and axillobifemoral bypass grafting procedure,
Table I. Thirty-day morbidity and mortality
Reason for Time since
Patient Age primary first graft Secondary
number (years) operation (months) presentation Microbiology Complications
1 67 Elective AAA 60 Pyrexia, sciatica, abdominal mass Streptococcus viridans None
2 75 Elective AAA 15 Graft occlusion, false aneurysm Escherichia coli None
3 68 ABG 4 Groin abscess, perigraft collection Streptococcus faecalis None
4 49 Elective AAA 64 Bleeding aortoenteric fistula Staphylococcus epidermidis, Prolonged ileus, 
Streptococcus milleri, peritoneal
Haemophilus parainfluenzae candidiasis
5 65 Elective AAA 5 Ruptured proximal false aneurysm Staphylococcus epidermidis Renal impairment, 
no dialysis
6 78 Ruptured AAA 2 Graft-enteric fistula, psoas abscess, Escherichia coli Death caused by 
acute MI duodenal leak and 
biliary peritonitis
7 64 ABG 57 Graft-enteric fistula, septic emboli, Streptococcus faecalis None
false aneurysm
8 69 ABG 120 Three false aneurysms Negative cultures None
9 46 Ruptured AAA 2 Psoas abscess MRSA Death caused by 
aortic candidiasis 
leading to rupture
10 70 Elective AAA 18 Septic shock Klebsiella pneumoniae, None
Streptococcus faecalis
11 67 Ruptured AAA 4 Aortoenteric fistula MRSA None
AAA, Abdominal aortic aneurysm; ABG, aortobifemoral bypass graft; MI, myocardial infarction; MRSA, methicillin-resistant
Staphylococcus aureus.
she died. At autopsy, there was no evidence of any
residual MRSA infection, but she had extensive
retroperitoneal candidiasis and a candidal aortitis
causing aortic rupture 1 cm above an intact proximal
aortic anastomosis.
One other patient undergoing postoperative
retroperitoneal antibiotic irrigation had peritoneal
candidiasis, but it resolved after cessation of irriga-
tion. One patient had a transient deterioration in
renal function, but no patients in this series required
dialysis or major limb amputation. The remaining
complication of note was profound anorexia, which
necessitated prolonged parenteral and then enteral
feeding, in the surviving MRSA patient who had an
infected hematoma after undergoing repair of a rup-
tured aneurysm 2 months earlier. As will be seen, we
suspect that this was a manifestation of ongoing
MRSA infection.
Of the nine survivors, seven remained alive and
clinically free of infection; two survivors were lost to
follow-up, one at 12 months and one at 15 months.
The 1-year survival rate was 64%. Of the remaining
five survivors, one has been asymptomatic for 75
months, three have been asymptomatic for more than
60 months, and one has remained clinically free of
infection for 35 months. However, two of the 30-
day survivors have subsequently died. The first (who
had MRSA anorexia in the early postoperative peri-
od) died 4 months postoperatively of pneumonia.
Although never proven at autopsy, we strongly sus-
pect that this patient had an ongoing MRSA infec-
tion. The second patient who subsequently died
originally had septic emboli in the right leg, a graft-
enteric fistula (with gallstones lying on the right
graft limb), and a bile-stained false aneurysm in the
right groin. The left graft limb and groin looked
normal, and because the left groin had been previ-
ously explored on a number of occasions, the first in
situ revascularization was extended down to the left
external iliac artery at the level of the inguinal liga-
ment (ie, leaving a small portion of the original
graft in the left groin). In retrospect, this was prob-
ably a mistake, because 12 months after his TGE
and in situ revascularization, the patient had an
apparently sterile left groin false aneurysm, which
was treated by means of an obturator bypass graft.
However, 8 months later (22 months after the first
operation for MAGI), he had a bleeding aortoen-
teric fistula and underwent a further TGE with
bipopliteal revascularization from his supracoiliac
aorta via both obturator foramina, but he died 2
weeks after this operation of acute respiratory dis-
tress syndrome and renal failure.
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DISCUSSION
Prosthetic graft infection is one of the most
dreaded complications of vascular surgery. Overall
rates for major graft infection average around 2%,
ranging from less than 1% to 6% in published
series.9-14 The treatment of infected aortic grafts is
difficult and is associated with high morbidity
rates10,11,13,15,16 and mortality rates.10,11,13,17
There are a number of important considerations
when dealing with aortic graft infection. The prima-
ry objective is eradicating the underlying infection.
The degree to which this can be achieved is limited
by two factors: the need to maintain adequate
peripheral perfusion while minimizing the morbidi-
ty and mortality in these compromised patients.
Previously, there have been two schools of thought
regarding management of aortic graft infection, the
conservative approach and the radical approach. The
conservative approach involved placing gentamicin
beads in the infected field or adjacent to the graft for
1 to 2 weeks. This method has been described in
small series and isolated case reports in combination
with graft excision to lower the risk of aortic stump
blowout and as a conservative method for treating
localized groin infections.18,19 Morris et al suggest-
ed treating graft infection with prolonged, high-
dose, local antibiotic irrigation therapy, systemic
antibiotic treatment, surgical debridement, and graft
conservation.20 Simple replacement of the prosthesis
followed by high-dose systemic antibiotics has not
been successful because of the failure of the antibi-
otics to achieve a minimum inhibitory concentration
in the inflamed tissues around the graft. Therefore,
these approaches have a limited success, but may be
appropriate in the treatment of the occasional high-
risk individual.7,21-23
The radical treatment consists of TGE, over-
sewing of the aortic stump, debridement of sur-
rounding tissues, and extra-anatomic bypass graft-
ing.13,24,25 However, this management is technically
complex and is associated with mortality rates of
24% to 70%.26-34 Other problems with this approach
include reduced long-term patency and high ampu-
tation rates.12,13,33,35 In addition, axillofemoral
reconstruction may also be associated with the com-
plications of gluteal ischemia, renal failure caused by
aortic stump thrombosis, reinfection of the femoral
end of the graft, and aortic stump blowout, which is
usually fatal. In addition to the high rate of throm-
bosis, recurrence of infection in the graft occurs in
approximately 20% of cases.33 In view of all these
problems, alternative strategies of revascularization
have been investigated.
The use of antibiotic-bonded grafts is an attractive
surgical adjunct for the treatment of infected aortic
prostheses when in situ replacement is deemed feasi-
ble. A number of different conduits have been used,
including autologous vein,36-38 cryopreserved arterial
allografts,39 polytetrafluoroethylene,40,41 and antibi-
otic-bonded Dacron.1-4 Initial attempts at in situ
replacement with graft and antibiotic combinations
were unsuccessful because of the rapid attenuation of
drug concentrations in and around the replacement
graft site.42 Coating the prosthesis with a material
(collagen or gelatin) to provide a bond between the
graft and the antibiotic has enabled such grafts to
retain antimicrobial activity for prolonged periods.
Rifampicin is a particularly useful antibiotic in this sit-
uation, because it has a broad spectrum of activity
against gram-negative and gram-positive organisms,
especially S aureus.43 It is relatively hydrophobic and
therefore does not dissolve into the circulation rapid-
ly. It is also used relatively infrequently in vascular
surgery and is less likely to lead to bacterial resistance.
Rifampicin-bonded grafts have been shown to be
resistant to in vitro infection with S aureus for as long
as 3 weeks.44 These factors make TGE and in situ
replacement with a rifampicin-bonded prosthesis a
feasible option in treating major graft infection. We
previously described our initial results with this tech-
nique.3 It has also been used in other centers with
good early results.2,4
Since publishing our initial results in 5 cases, we
have treated six more patients by means of this
approach, and we now have a longer follow-up peri-
od. Seven patients originally underwent elective
repair, and four patients underwent emergency
repair. The early (within 30 days) and late mortality
rates were 18% and 36%, respectively. Both of the
early deaths and one late death occurred in patients
who had originally undergone emergency repair of a
ruptured abdominal aortic aneurysm (AAA). These
figures are comparable with those of a number of
other series, which used either extra-anatomic bypass
grafting procedures or in situ replacement.35,45-47
Our results suggest a poorer long-term outcome
(75% mortality rate) in the group of patients who had
originally undergone emergency procedures. The
postoperative mortality rate was also significantly
higher in those cases that involved aortoenteric fistu-
lae (3 of 5 presentations), as opposed to one of the
remaining 11 presenting symptoms. The long-term
mortality rate from graft-enteric fistula has been
reported as 48% to 83%.46-48 This may be because of
the acute presentation of these cases and the chal-
lenging nature of the subsequent surgery.
However, with regard to other complications,
the in situ repairs may fare better. In one recent
study, the limb-loss rate was 10% for in situ replace-
ment versus 24% for extra-anatomic bypass grafting
procedures.48 None of the patients in our series sus-
tained limb loss. The limb-loss rate appears to be
similarly low with other types of in situ procedure:
6% to 10% for reconstruction with autologous
vein36,50; 5% for aortic allograft51; and 0% for poly-
tetrafluoroethylene replacement.41 The rate of sec-
ondary intervention to salvage limbs was also low in
all these groups (0% to 12%). However, the outcome
for limb loss or graft revision is less favorable with
extra-anatomic bypass grafting procedures, which
have amputation rates of 19% to 27%.13,33,45,52
Extra-anatomic bypass grafting procedures have a
risk of 9% to 30% of aortic stump blowout when
used in this scenario.46,49 To date, anastomotic
blowout has not been a problem with in situ replace-
ment with a rifampicin-bonded graft, although one
patient in our series died as a direct result of aortic
candidiasis, which caused aortic rupture above an
intact anastomosis.
Another factor that is likely to affect the man-
agement of vascular graft infection greatly in the
future is MRSA. The proportion of S aureus causing
hospital-acquired infection that is methicillin resis-
tant has risen from a range of 3% to 5% in the early
1980s to a range of 28% to 54% a decade later.53-55
Despite the widespread implementation of screening
and isolation programs, these multidrug-resistant
organisms are becoming increasingly common in
surgical and intensive care units. A number of factors
have been associated with a predisposition to infec-
tion with MRSA, including long-term central
venous access, prolonged urinary catheterization,
broad spectrum antibiotic use (especially third gen-
eration cephalosporins), blood transfusion, and
length of preinfection hospital stay.53-56 All these
factors are prevalent in patients undergoing elective
and ruptured AAA surgery and increase such
patients’ risk of acquiring MRSA infection.
The prevalence of S aureus infection was relative-
ly low (18%) in our series, whereas others have
encountered it in 50% to 86% of cases.57,58 The two
patients with S aureus infection in our series had
required prolonged intensive care treatment after
repair of a ruptured AAA. MRSA was isolated in
both of these cases after TGE and in situ replace-
ment. In view of this, we were not able to institute
the appropriate high-dose systemic antibiotic regi-
men from the time of removal and replacement of
the prosthesis. The sensitivity of MRSA to rifampicin
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is not known, and this may have allowed recoloniza-
tion of the grafts. Torsello recently reported a death
after in situ replacement with a rifampicin-bonded
Dacron graft, in which the organism was a mul-
tidrug-resistant (including rifampicin) S aureus.2
The dangers of infection by MRSA are highlighted
by the eventual death of both of our infected
patients; the first died of candidal aortitis and subse-
quent rupture and the second died of probable
MRSA pneumonia after a prolonged period of ill-
ness. In our opinion, this poor outcome in patients
with MRSA justifies the need for a more aggressive
antibiotic regimen (vancomycin, teicoplanin, or
both) in cases in which MRSA is likely. However, we
are worried about reports emerging on vancomycin-
and teicoplanin-resistant strains of MRSA.59
Alternative approaches to the treatment of MAGI
with MRSA have been reported. Attempts at in situ
revascularization with autogenous material,50 such as
lower-extremity veins, have been unsuccessful in the
presence of this difficult organism.60 Accordingly,
now when a patient has a suspected MAGI within 3
months of the original procedure (ie, this is probably
a virulent organism) or when preoperative cultures
are positive for MRSA, our policy is to perform a
TGE and extra-anatomic bypass grafting procedure.
Until more is known about the effectiveness of the
rifampicin-bonded graft in resisting MRSA infection,
extra-anatomic bypass grafting is perhaps a safer
option, despite its own potential deficiencies. 
In four of our early cases, a Foley catheter was
placed in the retroperitoneum to allow postoperative
irrigation with a solution containing appropriate
antibiotics. This technique was abandoned after two
of the patients developed severe retroperitoneal can-
didiasis. This may be related to fungal overgrowth
after eradication of the original infecting organism
and the prolonged presence of a foreign body.
Although we have not found a role for the routine
use of retroperitoneal irrigation, we accept that
other centers have found it to be beneficial.6
In conclusion, our initial optimism about the use
of TGE plus in situ replacement with rifampicin-
bonded Dacron grafts in the management of major
aortic graft infection has been tempered by addi-
tional experience. The limitations of the graft in pro-
tecting against the growing problem of MRSA infec-
tion may limit its usefulness if MRSA becomes even
more prevalent and unpredictable in the future.
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